07:18 AM EDT, 03/28/2025 (MT Newswires) -- CureVac ( CVAC ) said Thursday the European Patent Office upheld a modified version of its mRNA patent after dismissing most of BioNTech's (BNTX) challenge in a case tied to their dispute over vaccine technology.

A hearing to determine whether BioNTech infringed the amended patent is scheduled for July 1 in a Dusseldorf court, CureVac ( CVAC ) said.

CureVac's ( CVAC ) shares were up more than 13% in recent Friday premarket activity.